Topics: Practice Tools and Tips | Psychopharmacology | Psychotherapy | Substance Abuse

As marijuana has gained acceptance—it can now be prescribed to treat a wide variety of medical conditions in 28 states and Washington, DC—there has also been a shift in attitudes toward other mind-altering substances that, despite their reputation as drugs of abuse, show promise as therapeutic agents.

Topics: Practice Tools and Tips | Psychopharmacology | Psychotherapy | Substance Abuse

Ms. Petitt’s manages the program that selects and trains researchers for the MDMA-assisted psychotherapy protocols MAPS Public Benefit Corporation is conducting. The program has reviewed 300 applicants, and is in the midst of training 80 people who will work on therapy teams for Phase 3 trials. In addition to the training program, Ms. Petitt has also served as co-therapist on the MAPS-sponsored Phase 2 trial of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness.

Topics: Psychopharmacology | Psychotherapy | Research Update

Patients receiving buprenorphine for opioid use disorder are typically also referred for psychotherapy, either individual or group. However, several studies have failed to show that therapy improves outcomes in buprenorphine treatment program

Topics: Addiction | Practice Tools and Tips | Psychopharmacology | Psychotherapy | Research Update | Substance Abuse

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits.